CRS Bio
San Francisco
About CRS Bio
CRS Bio develops antibodies to treat chronic rhinosinusitis. The company was incorporated in 2016 and is based in San Francisco, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $8.4M
- Last round: Series Unknown (Oct 2016)
- Phone: +1 415 835 3900
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/crs-bio-133497 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.